GlassScriptPhysician profile
Suhyla Alam
NPI 1023438199
$2,850.28
in general payments reported to CMS, 2019-2025
15 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 82% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.15 · 2020: $226 · 2021: $97.26 · 2022: $140 · 2023: $605 · 2024: $579 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Travel and Lodging: $165 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.69 |
| Travel and Lodging | $164.58 |
| Education | $107.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $675.14 | 2020-2025 | Dupixent |
| Inspire Medical Systems, INC. | $667.76 | 2023-2025 | Inspire |
| Optinose US, INC. | $434.82 | 2020-2025 | |
| Glaxosmithkline, LLC. | $394.45 | 2020-2025 | Nucala |
| Genzyme Corporation | $263.89 | 2021-2025 | |
| Aerin Medical INC. | $99.87 | 2023-2025 | |
| Stryker Corporation | $85.22 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $53.56 | 2025 | Tezspire |
| Amgen INC. | $50.77 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $32.00 | 2021-2023 | |
| Kaleo, INC. | $26.25 | 2020 | |
| Paratek Pharmaceuticals, INC. | $18.73 | 2025 | Xhance |
| Medtronic, INC. | $17.02 | 2022 | |
| Hikma Pharmaceuticals USA | $17.00 | 2025 | Ryaltris |
| Intersect Ent, INC. | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suhyla Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.